Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study) Catheterization and Cardiovascular Interventions, 04/25/2012

Liu P et al. – The result of the ISCAP study will provide important evidence on the efficacy and safety of periprocedural serial intensive statin treatment in Asian patients with coronary artery disease undergoing selective percutaneous coronary intervention (PCI).

• Approximately 1,100 patients with stable angina or non–ST elevation acute coronary syndrome undergoing selective percutaneous coronary intervention (PCI) are enrolled in this study.
• Patients are randomized either to the experimental group (80 mg atorvastatin 80 mg/day × 2 days before and 40 mg/day × 30 days after PCI) or to the control group (usual care).
• Creatine kinase–MB (CK–MB), troponin I (cTnI), and serum creatine are measured at 24 hours after the procedure.
• The total follow–up period is 6 months.
• The primary objective is to evaluate the efficacy of intensive atorvastatin treatment compared with usual care in reducing 30–day primary cardiovascular endpoints in patients undergoing selective PCI.
• Secondary endpoints are changes in myocardial biomarkers (cTnI, CK–MB) and hs–CRP, CIN morbidity, 6–month clinical outcomes, and safety.